Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center

Post time 4 day(s) ago

journal：Clinical Lung Cancer

Authors：Troy J. Kleber; Sage A. Copling; Andrew D. Kim; César P. Márquez; Wenli Dong; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; J. Jack Lee; Yuliya Kitsel; Xiaoyu Han; Sherif M. Ismail; Hui Xu; Ivan Coronado; Zhongxing Liao; Joe Y. Chang; Aileen Chen; Saumil Gandhi; Matthew S. Ning; Quynh-Nhu Nguyen; Michael S. O’Reilly; David Qian; James W. Welsh; Stephen G. Chun; Tina Cascone; Jianjun J. Zhang; Don L. Gibbons; Mehmet Altan; Ara A. Vaporciyan; David C. Rice; Ravi Rajaram; Reza J. Mehran; Mara B. Antonoff; Kyle G. Mitchell; Annikka Weissferdt; John V. Heymach; Jia Wu; Steven H. Lin; Julianna K. Bronk

Published date：2026-10-

DOI：10.1016/j.cllc.2026.08.007

PDF link：https://www.sciencedirect.com/sc ... 525730426001117/pdf

Article link：https://doi.org/10.1016/j.cllc.2026.08.007

Article Source：Elsevier BV。

Remark：

Post time 4 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center